Phase I/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with advanced melanoma or non-small cell lung cancer
43rd ESMO Congress (ESMO), Munich, Germany, 19 - 23 October 2018, vol.29, pp.413, (Summary Text)
- Publication Type: Conference Paper / Summary Text
- Volume: 29
- City: Munich
- Country: Germany
- Page Numbers: pp.413
- Istanbul University Affiliated: Yes